Corvus Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $969.1M
- as of Sep 30, 2026
- Shares Outstanding
- 84.1M
- Free Float
- 64.3%
Income Statement
- Operating Income
- -$43.0M
- Net Income
- -$15.3M
- EBITDA
- -$42.9M
Cash Flow
- Free Cash Flow
- -$33.0M
- FCF Yield
- -3.4%
- Owner FCF Yield
- -4.0%
Balance Sheet
- Cash & Equivalents
- $4.6M
Returns & Capital
- SBC, 3Y Avg
- $3.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$33.0M | — |
| FY2023 | — | -$24.0M | — |
| FY2022 | — | -$27.3M | — |
| FY2021 | — | -$36.7M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges